Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 3, 2015, Pages 273-280

  Bermel, R A ^a   Hashmonay, R ^b   Meng, X ^b   Randhawa, S ^b   Von Rosenstiel, P ^b   Sfikas, N ^b   Kantor, D ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Neurologia   (United States)

Author keywords

Cardiac safety; Depression; Drug interactions; Fingolimod; Multiple sclerosis; Serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FINGOLIMOD; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAL SIGN; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; CITALOPRAM; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FINGOLIMOD HYDROCHLORIDE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84930180419     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.04.002     Document Type: Article

References (26)

1. H.C. Bazett An analysis of the time relation of electrocardiograms Heart 7 1920 353 370
2. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, and G. Francis Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 2010 883 897
3. P.A. Calabresi, E.W. Radue, D. Goodin, D. Jeffery, K.W Rammohan, and A.T. Reder Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 545 556
4. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
5. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, and X. Montalban Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
6. J. DiMarco, P. O'Connor, J.A. Cohen, A.T. Reder, L. Zhang-Auberson, and D. Tang First-dose effects of fingolimod: pooled safety data from three phase 3 studies Mult Scler Relat Disord 3 2015 629 638
7. European Medicines Agency. Annex I. Summary of product characteristics. Gilenya (fingolimod), (http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002202/WC500104528.pdf); 2011 [accessed 27.08.14].
8. B. Fermini, and A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development Nat Rev Drug Discov 2 2003 439 447
9. L.S. Fridericia Die systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken Acta Med Scand 53 1920 469
10. K.A. Funk, and J.R. Bostwick A comparison of the risk of QT prolongation among SSRIs Ann Pharmacother 47 2013 1330 1341
11. Goldman Consensus Group The Goldman consensus statement on depression in multiple sclerosis Mult Scler 11 2005 328 337
12. ICH. ICH harmonised tripartite guidelines for good clinical practice E6(R1). In: Proceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Geneva, (http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf); 1996 [accessed 27.08.14].
13. L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, and C.H. Polman Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140
14. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
15. M.W. Koch, A. Glazenborg, M. Uyttenboogaart, J. Mostert, and J. De Keyser Pharmacologic treatment of depression in multiple sclerosis Cochrane Database Syst Rev 2011 Issue 2. Art. No.: CD007295
16. M. Korostil, and A. Feinstein Anxiety disorders and their clinical correlates in multiple sclerosis patients Mult Scler 13 2007 67 72
17. J. Morganroth, F.V. Brozovich, J.T. McDonald, and R.A. Jacobs Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia Am J Cardiol 67 1991 774 776
18. S.B. Patten, C.A. Beck, J.V. Williams, C. Barbui, and L.M. Metz Major depression in multiple sclerosis: a population-based perspective Neurology 61 2003 1524 1527
19. L.P. Perez, R.S. Gonzalez, and E.B. Lazaro Treatment of mood disorders in multiple sclerosis Curr Treat Options Neurol 17 2015 323
20. R. Schmouder, D. Serra, Y. Wang, J.M. Kovarik, J DiMarco, and T.L. Hunt FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects J Clin Pharmacol 46 2006 895 904
21. US Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; 2005.
22. US Food and Drug Administration. Effexor (venlafaxine hydrochloride) prescribing information, (http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020151s031s055s058s060lbl.pdf); 2012a [accessed 05.02.15].
23. US Food and Drug Administration. Gilenya prescribing information, (http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022527s008lbl.pdf); 2012b [accessed 13.01.15].
24. US Food and Drug Administration. Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses; 2012c.
25. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride) prescribing information, (http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021427s037s042lbl.pdf); 2014 [accessed 05.02.15].
26. WMA. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects, (www.wma.net/en/30publications/10policies/b3/index.html); 2013 [accessed 27.08.14].